Leo Pharma announced that Enstilar (calcipotriene and betamethasone dipropionate) foam has been approved for the topical treatment of plaque psoriasis in adults aged ≥18 years.

Enstilar is an alcohol-free foam in a pressurized spray can. It is combination of calcipotriene, a vitamin D analog, and betamethasone dipropionate, a corticosteroid. The exact mechanisms of their actions in plaque psoriasis are unknown.

The approval of Enstilar was based on data from a Phase 3 trial where treatment with Enstilar resulted in over half the patients being “Clear” or “Almost Clear” by Week 4 as assessed by the Investigator Global Assessment (IGA) score of disease severity. Also, over half the patients treated achieved a 75% improvement in the Psoriasis Area and Severity Index (PASI) score from baseline.

RELATED: Two Experimental Drugs Promising for Psoriasis Rx

It is supplied as a 0.005%/0.064% strength in 60g cans. Each gram delivers 52.2mcg calcipotriene (equivalent to 50mcg calcipotriene) and 0.643mg betamethasone dipropionate (equivalent to 0.5mg betamethasone).

For more information call (877) 494-4536 or visit Enstilar.com.